Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 243 Squamous Cell Carcinoma of Head and Neck 137 Melanoma 137 Parkinson Disease 4, Autosomal Dominant Lewy Body 119 Neoplasm Metastasis 105 Triple Negative Breast Neoplasms 96 Neoplasms 90 Lung Neoplasms 88 Breast Neoplasms 79 Colorectal Neoplasms 70 Carcinoma, Renal Cell 69 Head and Neck Neoplasms 59 Urinary Bladder Neoplasms 50 Stomach Neoplasms 48 Ovarian Neoplasms 46 Endometrial Neoplasms 45 Carcinoma, Transitional Cell 44 Carcinoma, Hepatocellular 35 Uterine Cervical Neoplasms 34 Pancreatic Neoplasms 34 Esophageal Neoplasms 27 Recurrence 25 Prostatic Neoplasms 25 Carcinoma, Squamous Cell 25 Carcinoma 25 Sarcoma 24 Brain Neoplasms 23 Glioblastoma 22 Hodgkin Disease 19 Cholangiocarcinoma 19

Interventions

Etoposide 2 pembrolizumab 1 olaparib 1 niraparib 1 atezolizumab 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC,Extensive Stage × pembrolizumab × 1 year × Clear all

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡